NCT00322517 - Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2009

Conditions

Breast Neoplasms

Interventions

DRUG

SU014813

100 mg capsule/day for 6 cycle of 21 days

Trial Locations (22)

20133

Pfizer Investigational Site, Milan

20246

Pfizer Investigational Site, Hamburg

30035

Pfizer Investigational Site, Mirano (VE)

33100

Pfizer Investigational Site, Udine

35043

Pfizer Investigational Site, Marburg

38104

Pfizer Investigational Site, Memphis

38120

Pfizer Investigational Site, Memphis

38671

Pfizer Investigational Site, Southaven

38834

Pfizer Investigational Site, Corinth

39130

Pfizer Investigational Site, Magdeburg

66013

Pfizer Investigational Site, Chieti Scalo

90095

Pfizer Investigational Site, Los Angeles

90404

Pfizer Investigational Site, Santa Monica

91105

Pfizer Investigational Site, Pasadena

91355

Pfizer Investigational Site, Valancia

1081 HV

Pfizer Investigational Site, Amsterdam

3075 EA

Pfizer Investigational Site, Rotterdam

Unknown

Pfizer Investigational Site, Manchester

SM2 5PT

Pfizer Investigational Site, Sutton

EH4 2XU

Pfizer Investigational Site, Edinburgh

SE1 9RT

Pfizer Investigational Site, London

SW3 6JJ

Pfizer Investigational Site, London